DREADD agonist 21 selectively activates hM3Dq and hM4Di DREADDs, derived from the human muscarinic acetylcholine M3 (hM3) receptor, without affecting the hM3 receptor itself. It has weaker affinities for other receptors (histamine H1, serotonin 5-HT2A, 5-HT2C, and α1A-adrenergic). Used in chemogenetics, it remotely controls neuronal activity, permeates the brain effectively, activating hM3Dq and inhibiting hM4Di DREADDs in vivo. This dihydrochloride salt formulation ensures water solubility.
Usually ships within 24 hours.